RSS

Ablynx

Sanofi has acquired all outstanding shares, warrants and convertible bonds of Ablynx, following the expiration of the squeeze-out procedure. more

News

Biopharmaceutical companies, Sanofi and Ablynx, have announced the successful results of the initial tender offer period for Sanofi to acquire outstanding shares of Ablynx. more

News

Sanofi is to acquire all outstanding ordinary shares of a biopharmaceutical company that is currently focused on the discovery and development of Nanobodies, Ablynx. more

News

Biopharmaceutical company, Ablynx, and Sanofi have entered into a strategic collaboration for the development of Nanobody based therapeutics for the treatment of immune-mediated inflammatory diseases. more

News

Preparation of a pre-clinical package for a novel Nanobody (ALX-1141) in osteoarthritis has been completed by Ablynx and accepted by Merck as a part of the ongoing collaboration between the two companies. more

News

Biopharmaceutical company, Ablynx, has announced the completion of patient recruitment for its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). more

News

Ablynx has completed target enrolment of a phase I/IIa safety study of its anti-RSV nanobody, ALX-0171 for the treatment of respiratory syncytial virus (RSV) infection in infants more

News

Ablynx and Novo Nordisk will collaborate to discover and develop multi-specific nanobody drug candidates with an option to expand the agreement to include a second nanobody programme more

News